LONG BEACH, Calif. — In this video, John W. Kitchens, MD, discusses the long-term follow-up of the phase 3 Archway study evaluating Susvimo implanted in patients with neovascular age-related macular degeneration.
“Five years of the Susvimo port delivery system [ranibizumab injection, Genentech] for wet macular degeneration shows excellent disease control with a great safety profile and a continued 6-month durability for over 95% of patients,” Kitchens, of Retina Associates of Kentucky, told Healio at the American Society of Retina Specialists annual meeting.